Swedish Orphan Biovitrum Ab · OMXSTO:SOBI
Swedish Orphan Biovitrum Ab — Sobi — Investor Presentation (July 2025)
34 slides from Swedish Orphan Biovitrum Ab's investor presentation, July 2025
Slide 1: This is Sobi
This is Sobi D Investor presentation July 2025
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains certain forward-looking statements with respect to certain of the Company’s current expectations and projections about future events. These statements, which sometimes use words such as “intend,” “proposed,” “plan,” “expect,” and words of similar
Slide 3: Table of contents
Table of contents Slide Sobi Key facts and business model 4 Latest results – Q2 2025 and business area update 15 Sustainability at Sobi 24 Pipeline and upcoming news flow 28 IR contacts 31 Notes 32
Slide 4: Sobi: Global biopharma company developing and commercialising rare disease therapies
Sobi: Global biopharma company developing and commercialising rare disease therapies Clear strategy with proven execution: • Identify: Successful BD track record building pipeline via partnerships and acquisitions • Unlock: Deep clinical-stage pipeline spanning multiple rare disease areas • Level Up
Slide 5: Rare diseases are an attractive market and expected to grow faster than general pharma
Rare diseases are an attractive market and expected to grow faster than general pharma • ~10,000 rare disease have been identified with only an Sobi well positioned within rare diseases estimated 130 with marketed treatments Current Sobi areas • High medical unmet need and treatments offering signif
Slide 6: Business model - source, develop and commercialise in the rare disease space
Business model - source, develop and commercialise in the rare disease space 2018 2019 2020 2022 2023 Acquisitions Identify Licensing Unlock Driving clinical development with potential new molecules and expansion of existing medicines Europe +14% 2024: Revenue: SEK 26,027 M North America + 4% Level
Slide 7: Strong record of successful achievements in delivering medicines to rare disease patients
Strong record of successful achievements in delivering medicines to rare disease patients around the world Selected examples from the Sobi portfolio Identify Novimmune Dova Apellis CTI Pharma ITP - FDA approval 2018 pHLH - FDA approval 2018 PNH - EU approval 2021 MF – FDA approval 2022 EU approval 2
Slide 8: Next wave of catalysts to drive growth
Identify Next wave of catalysts to drive growth Asset Indication Phase 2 Phase 3 Registration C3G and IC-MPGN Pivotal VALIANT data presented at ASN Kidney Week 2024; Aspaveli/Empaveli Filed in EU February 2025 (pegcetacoplan) Post-HSCT-associated microangiography HLH / MAS in Stills disease FDA prio
Slide 9: Strong progress in pipeline in 2024
Unlock Strong progress in pipeline in 2024 Haemophilia-A: Altuvoct EU approval Aspaveli/ C3G and IC-MPGN: C3G and IC-MPGN: PNH: Empaveli Positive VALIANT Phase 3 data Submission to EMA* First-line approval in EU VEXAS: Vonjo IND granted by FDA ITP: Paediatric extension Doptelet submitted to FDA ITP:
Slide 10: Growth driven by core business area and all regions
Level Up Growth driven by core business area and all regions Sales (SEK B) Sales (SEK B) Haematology Immunology Specialty Care Europe North America Royalty including Beyfortus US International 26 26 22.1 18.8 22.1 15.3 15.5 18.8 14.2 14.2 15.3 15.5 9.1 9.1 2018 2019 2020 2021 2022 2023 2024 2018 201
Slide 11: Looking ahead to 2025
Looking ahead to 2025 Anticipated major pipeline news flow 2025 outlook 2025 Aspaveli / Empaveli – Nephrology • EU regulatory decision Revenue • Japan regulatory submission Anticipated to grow by a high-single Gamifant1 – HLH / MAS • US regulatory decision digit percentage at CER • Japan regulatory
Slide 12: Sobi's near term building block of the future
Sobi’s near term building block of the future Investment in 2025 for multiple launches in 2025/26 2 3 4 Major launches Key filing Priority development projects in area of high 1. Altuvoct 1. Gamifant - HLH/MAS unmet medical need 2. Vonjo 2. Aspaveli - C3G/IC- MPGN 1. Gamifant - IDS 3. NASP - uncontr
Slide 13: Reason to Invest
Reason to Invest Sobi: Unlocking the potential of breakthrough therapies, transforming everyday life for people living with rare diseases Solid foundations Bright future • Track record of identification of assets at late stage • Growing on market portfolio with active launches (relatively derisked)
Slide 14: Management Team
Management Team 14 sobi.com/executive committee
Slide 15: Latest results Q2 2025 and business area update
Latest results Q2 2025 and business area update
Slide 16: Q2 Highlights: Growth, Portfolio Expansion & Pipeline Milestones
Q2 Highlights: Growth, Portfolio Expansion & Pipeline Milestones Continued Portfolio growth, +22% at CER Revenue Q2: SEK 6,175 M, +22% Adjusted EBITA margin Q2: 34% Strategic portfolio1 accounts for 55% of revenue in the quarter - growing 65% at CER • Altuvoct® SEK 627 M • Gamifant® SEK 632 M, +33%
Slide 17: Delivering strong Q2 growth & advancing long-term value
Delivering strong Q2 growth & advancing long-term value Underpinned by robust portfolio performance and global delivery Revenue by segment Revenue by region Q2 2025 change contrib. Q2 2025 change SEK M % % SEK M % Haematology 4,570 +27 74 Europe 2,626 +21 – Haemophilia 2,699 +24 43 North America 2,1
Slide 18: Strong momentum across the portfolio in Q2
Strong momentum across the portfolio in Q2 Second quarter 2025 Haematology • Haemophilia A sales: Growing 32% driven by robust Elocta 991 -18% Altuvoct launch Altuvoct 627 >200% Alprolix 565 +7% • Doptelet: Continued strong demand across markets Altuviiio royalty 248 +98% with 43% growth Other Haem
Slide 19: Altuvoct: Launches continue in Europe and Middle East
Altuvoct: Launches continue in Europe and Middle East Haemophilia A sales (Altuvoct +Elocta) grew 32% in Q2 Haemophilia A sales SEK 1,618 M +32% Q2 Altuvoct launch: • Second quarter 2025 sales of SEK 627 M • Strong launch progress with initial sales in 17 countries led by Germany, Switzerland, and S
Slide 20: Aspaveli: Best-in-class Phase 3 efficacy data, on track for EU nephrology launch in 2026
Aspaveli: Best-in-class Phase 3 efficacy data, on track for EU nephrology launch in 2026 Aspaveli/Empaveli SEK 304 M +28% Q2 PNH • Continued growth across markets with strong YoY growth, competitive pressure in PNH growing in Europe Nephrology* • EU: CHMP opinion expected by end 2025 • Best in class
Slide 21: Vonjo: Demand growing but sales impact from gross to net adjustments
Vonjo: Demand growing but sales impact from gross to net adjustments Vonjo SEK 302 M -4% Q2 • Demand increasing vs PY in Q2: +11% volume growth • Net sales -4% in Q2 • GTN impact due to recent changes in reimbursement Strategic progress: (Focus: label expansion, guideline support, Internationalizati
Slide 22: Gamifant: US FDA approves MAS in Still's disease
Gamifant: US FDA approves MAS in Still’s disease Strong sales growth driven by an increase in the number of patients on treatment and positive patient mix Gamifant SEK 632 M +33% Q2 FDA approves, after priority review Gamifant as first-ever treatment for adults and children with Macrophage Activatio
Slide 23: Q2 2025 Revenue and profit & loss
Q2 2025 Revenue and profit & loss Q2 Q2 Full-year Total revenue (SEK M) Amounts in SEK M 2025 2024 Change 2024 Total revenue 6,175 5,442 13% 26,027 Haematology Immunology Specialty Care Adjusted Gross profit 1,2 4,781 4,166 15% 20,326 7 436 6 894 385 Adjusted Gross margin 1,2 77% 77% 78% 6 465 311 6
Slide 24: Sobi Outlook 2025
Sobi Outlook 2025 Key considerations for 2025 2025 outlook • Altuvoct launch progress Revenue • Continued progress with commercial portfolio Anticipated to grow by a high single- • Beyfortus royalty digit percentage at CER • Launch preparation • In US for NASP in uncontrolled gout • In Europe for As
Slide 25: Sustainability at Sobi
O) @sobl Sustainability at Sobi
Slide 26: Sustainability strategy drives business priorities
Sustainability strategy drives business priorities Commitment to patients Responsible behaviour Sobi’s climate targets • Access to treatment • Safe, fair, and healthy work approved by SBTi • Patient centricity and engagement • Inclusive, diverse workplace • Patient and product safety • Lower environ
Slide 27: Commitment to patients
Commitment to patients For more details: Sustainability performance | Sobi Access to treatment Humanitarian aid Patient centricity ~ 42,000 people treated* with • Four international patient councils to medicines from Sobi. advise on early clinical development. • 525 employees completed training in p
Slide 28: Always act responsibly
Always act responsibly For more details: Sustainability performance | Sobi Caring for employees Reduced footprint Responsible sourcing Compliance • Gender composition (%) • A 77% reduction in CO2- intensity between 2016 95% Mean score 64 95% and 2023 (from 0,3 to 0,07 between completed Code of of So
Slide 29: Pipeline and upcoming news flow
Pipeline and upcoming news flow
Slide 30: Solid pipeline progress in Q2 2025
Solid pipeline progress in Q2 2025 C3G and IC-MPGN Aspaveli/ VALIANT 52-week: consistent efficacy & safety Empaveli TA-TMA Discontinued after Phase 2 strategic review HLH/MAS in Still’s disease Gamifant FDA approved extended indication Uncontrolled gout NASP FDA rolling submission completed VEXAS Vo
Slide 31: Progress to be continued in 2025-26
Progress to be continued in 2025-26 Anticipated pipeline news flow 2025 H2 2026 Aspaveli – C3G & IC-MPGN Aspaveli – C3G & IC-MPGN o EU CHMP opinion o EU regulatory decision o Japan regulatory submission o Japan regulatory decision Gamifant – HLH / MAS in Still’s disease Gamifant – HLH / MAS in Still
Slide 32: Sobi IR contacts
Sobi IR contacts Investors page on sobi.com
Slide 33: Notes on Haemophilia and RSV business
Notes on Haemophilia and RSV business Haemophilia • Sobi and Sanofi collaborate on the development and commercialisation of Alprolix and Elocta/Eloctate. The companies also collaborate on the development and commercialisation of efanesoctocog alfa, or Altuviiio in the US. • Sobi has final developmen
Slide 34: Thank you
Thank you Sobi is a trademark of Swedish Orphan Biovitrum AB (publ). © 2023 Swedish Orphan Biovitrum AB (publ) – All rights reserved Swedish Orphan Biovitrum AB (publ) SE-112 76 Stockholm • Sweden www.sobi.com